healthNewsغير مصنف

AstraZeneca digs deeper into cancer with Innate stake

AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

اظهر المزيد

مقالات ذات صلة

زر الذهاب إلى الأعلى